Maryland Medical Assistance Plan and Health Insurance - Pharmacogenomic Testing - Required Coverage

SB 608 requires Maryland's Medicaid program (Maryland Medical Assistance Plan) and certain health insurers, nonprofit health plans, and health maintenance organizations to cover single-gene and multigene pharmacogenomic testing starting July 1, 2027. This applies specifically when a treating provider orders the test for patients with depression or anxiety who are considering a medication change, dose adjustment, or addition with a known gene-drug interaction. The bill limits prior authorization requirements to ensure timely access, mandating clear pathways, minimal documentation, and sufficient time for submissions without creating unnecessary delays. Noncompliance could result in penalties of up to $10,000 per violation plus $1,000 daily until resolved. The law aims to improve medication safety and effectiveness by making this genetic testing accessible for targeted patient groups.